Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Friday
Feb242012

Advanced Therapies Summit 2012, Amsterdam March 22, 2012

The Advanced Therapies Summit is the second edition of the successful Cell Therapy Summit Europe 2011. The newly-created European Alliance for Advanced Therapies (AAT) will host the Summit in collaboration with the global Alliance for Regenerative Medicine (ARM).

Program Advanced Therapies Summit 2012

The Advanced Therapies Summit will address the most important topics on the path of commercialization of advanced therapies, including manufacturing, regulatory requirements, financing and reimbursement. Different topics will be addressed from the perspectives of small and large companies, investors, regulators and other stakeholders.

Join the executives from the leading U.S. and European advanced therapies companies at the Advanced Therapies Summit 2012 in Amsterdam on March 22, following BIO-Europe Spring 2012.

The Summit will address the most important topics on the path of commercialization of advanced therapies, including manufacturing, regulatory requirements, financing and reimbursement.

Leading Companies from Europe and the US include:

Aastrom Biosciences
Advanced BioHealing
Adaptimmune
ARM
Athersys
CaridianBCT
DCPrime
Dendreon
EMA
Glycostem
Histocell
LTKfarma
Organovo
Pfizer
PharmaCell
Promethera
ReGenesys
ReNeuron
Roche
Scalable Life Sciences
Shire
Signifix
Sistemic
TiGenix
Urotiss

Space is limited. Register now via this link.

 

PrintView Printer Friendly Version

EmailEmail Article to Friend

References (2)

References allow you to track sources for this article, as well as articles that were written in response to this article.
  • Response
    Daily Dose Equities - Wall Street Analysis for Biotech Research - Daily Dose Newsroom - Advanced Therapies Summit 2012, Amsterdam March 22, 2012
  • Response
    Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Advanced Therapies Summit 2012, Amsterdam March 22, 2012

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Cardiovascular Research Foundation NYC Conference February 23-25 | Main | Baxter ($BAX) Completes Acquisition of Synovis »